tracken
MediWound Ltd. Aktie News
Neutral
GlobeNewsWire
●
etwa ein Monat alt
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
Neutral
GlobeNewsWire
●
etwa ein Monat alt
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin,...
Positiv
Seeking Alpha
●
etwa 2 Monate alt
MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the company has a solid cash runway, no debt, and recent strategic investments. NexoBrid's expanded approvals and rising hospital orders, plus a new facility, position MediWound for significant revenue growt...
Neutral
GlobeNewsWire
●
2 Monate alt
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Ann...
Neutral
Seeking Alpha
●
3 Monate alt
MediWound Ltd. (NASDAQ:MDWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Barry J.
Neutral
GlobeNewsWire
●
3 Monate alt
VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Tim...
Neutral
GlobeNewsWire
●
3 Monate alt
MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
